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Targeted Imaging Offers Advantages Over Physiological
Imaging for Evaluation of Angiogenic Therapy*
Albert J. Sinusas, MD, FACC
New Haven, ConnecticutA large population of patients suffering from ad-
vanced coronary artery disease and chronic myocar-
dial ischemia cannot be adequately managed by a
combination of antianginal medication and angio-
plasty or coronary artery bypass surgery. Therefore,
therapeutic stimulation of vascular growth in the
management of chronic myocardial ischemia seems
to be a useful strategy in treating such patients. A
number of recent clinical trials have examined the
role of therapeutic administration of molecular
regulators of blood vessel growth to promote vas-
cular development to treat ischemic heart disease
(1). The patients eligible for these therapeutic
angiogenic trials often have underlying ischemic but
viable “hibernating” myocardium, characterized by
See page 500
persistent myocardial dysfunction in the presence of
resting hypoperfusion or chronic myocardial stun-
ning due to repetitive episodes of stress-induced
ischemia in myocardial regions with severely im-
paired coronary flow reserve. Fallavollita et al. (2)
have established a porcine model of surgical amer-
oid implantation in which the physiologic and
structural features of chronically ischemic myocar-
dium remain constant for months. A recent review
suggests that such porcine models of chronic myo-
cardial ischemia may be ideally suited for evaluation
of therapeutic angiogenesis or other interventions
targeted to improve flow and function of chronically
dysfunctional myocardium (3).
In their paper in this issue of iJACC (JACC:
Cardiovascular Imaging), Johnson et al. (4) use a
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Yale University School of Medicine, New Haven, Connecticut.porcine ameroid constrictor model in the evaluation of
a radiolabeled peptide targeted at v3 integrin for
tracking the therapeutic efficacy of endomyocardial
injection of a naked plasmid-deoxyribonucleic acid
encoding the 165-amino-acid isoform of human vas-
cular endothelial growth factor (phVEGF165), dem-
onstrating that targeted single-photon emission com-
puted tomographic (SPECT) imaging of angiogenesis
may be a useful approach for monitoring angiogenic
therapy in the heart. This catheter-based endovascular
delivery approach was previously shown to be feasible
for gene transfer in porcine studies by Vale et al. (5)
using Noga electromechanical mapping; they were
also the first to establish Noga-directed myocardial
gene therapy in humans in 2001, injecting a plasmid
encoding vascular endothelial growth factor-2
(phVEGF-2) (6). A follow-up randomized, double-
blind, placebo-controlled trial of vascular endothelial
growth factor-2 therapy demonstrated a statistically
significant improvement in angina class and a trend
toward improvement in exercise duration and quality
of life in phVEGF-2–treated patients compared to
placebo-treated patients (7). Recently, the Euroinject
One clinical trial was reported for patients with
chronic angina and no-option for conventional revas-
cularization randomized to receive direct endomyocar-
dial injection of phVEGF165 or placebo (8). In the
phVEGF165 treatment group, there was a significant
improvement in stress-induced perfusion defects at 3
months compared with baseline, although this change
was not different than the control group. However,
there were significant improvements in wall motion in
the phVEGF165 treatment group compared with the
control group.
Despite the promising results seen in experimen-
tal animal studies and preliminary phase 1 clinical
trials with angiogenic therapy, randomized,
placebo-controlled, double-blind clinical trials of
VEGF and fibroblast growth factor-2 have in gen-
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512ral yielded mixed or somewhat disappointing re-
ults (9). This might be related to insensitivity of
ur existing imaging approaches for evaluation of
ngiogenesis.
In theory, myocardial angiogenesis should result in
mproved perfusion and tissue oxygenation, resulting
n reduced hypoxia, diminished myocardial ischemia,
nd improved regional left ventricular function.
herefore, angiogenesis may be indirectly evaluated
oninvasively by analysis of standard physiological
arameters, such as regional myocardial perfusion and
unction. However, it remains uncertain whether the
ffects of angiogenesis on perfusion would be better
valuated by analysis of changes in intravascular blood
olume, or vascular and/or perfusion reserve. Unfor-
unately, angiogenesis may also alter vascular perme-
bility and the effective vascular surface area for sub-
trate exchange, which can confound imaging
pproaches that use diffusible tracers. Nevertheless,
emonstration of physiological benefit remains a crit-
cal step in the development and evaluation of thera-
eutic angiogenesis. Positron emission tomographic
PET) perfusion tracers such as 13N-ammonia, 15O-
ater, or 82Rb would theoretically be preferred due to
he favorable characteristics of PET imaging in gen-
ral and the ability to define absolute regional myo-
ardial blood flow.
As reviewed in the preceding text, in the absence
f a direct biological marker of angiogenesis, the
valuation of therapeutic angiogenesis has focused
n a number of clinical end points or imaging of the
hysiological consequences of the therapeutic inter-
ention (10). However, there is a tremendous need
or development of noninvasive approaches for
irect evaluation of the molecular events associated
ith angiogenesis to more effectively track thera-
eutic angiogenesis.
Angiogenesis is a complex process, involving: 1)
egradation of the basal membrane surrounding the
arental vasculature; 2) migration of endothelial
ells or progenitor cells; 3) proliferation of quiescent
ndothelial cells to form new vessels; and 4) align-
ent and organization of endothelial cells to form
ubes (11). The process of angiogenesis involves the
nterplay of many cells including monocytes/
acrophages, mast cells, lymphocytes, connective
issue cells, pericytes, endothelial cells, and pluripo-
ent progenitor cells, all of which influence the
rocess by secreting soluble angiogenic and antian-
iogenic molecules and proteolytic enzymes. Several
pproaches appear to be feasible for imaging of the
olecular events. These include the use of labeledligonucleotides targeted to specific messenger ri- wonucleic acid (mRNA) sequences, short peptides
argeted to specific intracellular and cell surface
eceptors, and labeled ligand-avid imaging. Poten-
ial biological targets for imaging angiogenesis fall
nto 3 principal categories; 1) endothelial cell mark-
rs of angiogenesis; 2) nonendothelial cells involved
ith angiogenesis; and 3) markers of the extracel-
ular matrix (ECM).
A potential target for early detection of angio-
enesis would relate to the imaging of the favorable
onditions or molecular events associated with the
nitiation of the angiogenic process. The potential
or targeted imaging of VEGF121 receptors and
v3 integrin as markers of angiogenesis has been
emonstrated by several groups of investigators
12–17). Expression of VEGF is markedly in-
reased by hypoxia and mediates many cellular
unctions, including release of other growth factors,
ell proliferation, migration, survival, and angiogen-
sis (18). At least 5 isoforms of human VEGF-A
RNA encoding for monomer VEGF proteins of
21, 145, 165, 189, and 206 amino acids are
roduced by alternative splicing from a single gene.
n the study by Johnson et al. (4), they administered
hVEGF165 directly into the myocardium to induce
ocal angiogenesis.
The angiogenic response is modulated by the
omposition of the ECM and intercellular adhe-
ions, including integrins. Integrins are a family of
 heterodimeric cell surface receptors that mediate
ell–cell and cell–matrix adhesion through tightly
egulated interactions with ligands. Integrin-ligand
inding is dependent on conformational changes in
he integrin structure (19). From the imaging
tandpoint, targeting of v3 integrin has promise,
ecause expression and activation in quiescent en-
othelial cells is low, whereas “angiogenic” endo-
helial cells demonstrate marked up-regulation of
v3 integrin expression and activation. Investiga-
ors first proposed the potential noninvasive detec-
ion of tumor angiogenesis in vivo using magnetic
esonance imaging and a paramagnetic contrast
gent targeted to endothelial v3 integrin via the
M609 monoclonal antibody (20). However, tar-
eted in vivo imaging using similar monoclonal
ntibodies has been limited in the past by slow
learance of the tracer from the blood. Haubner et
l. subsequently reported the synthesis and charac-
erization of a series of radiolabeled v3 integrin
ntagonists, reporting kinetics in both in vitro and
n vivo preparations (21). Their work has focused
n the use of cyclic Arg-Gly-Asp (RGD) peptides,
hich are known to bind to v3 integrin.
p
p
o
o
t
a
i
b
i
o
a
p
i
s
i
p
g
e
h
a
d
o
e
T
i
p
p
p
c
i
a
r
t
a
c
c
m
u
c
o
c
h
r
p
c
o
s
t
i
i
p
T
n
R
p
m
p
e
P
m
m
m
(
h
i
a
t
t
c
u
i
o
i
s
s
f
c
c
l
l
c
r
a
g
i
i
o
v
s
f
i
u
M
a
p
c
m
l
i
n
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 , N O . 4 , 2 0 0 8
J U L Y 2 0 0 8 : 5 1 1 – 4
Sinusas
Editorial Comment
513Meoli et al. (12) were the first to report the
otential of a radiolabeled v3 integrin-targeted
eptidomimetic, 111In-RP748, for in vivo imaging
f myocardial angiogenesis. Subsequently, several
ther studies have demonstrated the potential of
argeted imaging of v3 integrin for imaging of
ngiogenesis in skeletal muscle or the myocardium
n response to ischemic injury (13–17). The study
y Johnson et al. (4) confirms the value of the v3
ntegrin-targeted imaging approach for assessment
f myocardial angiogenesis using an 123I-labeled
rginine-glycine-aspartic acid (RGD) peptide in
igs with chronic ischemia treated with direct
ntramyocardial injection of phVEGF165. In their
tudy, changes in expression/activation of v3
ntegrin were related to changes in more functional
arameters, such as myocardial perfusion and re-
ional mechanical function, although they did not
valuate potential changes in permeability, regional
ypoxia, or metabolism.
The study by Johnson et al. (4) appropriately uses
n established pig model of hibernating myocar-
ium to test 123I-Gluco-RGD for targeted imaging
f the v3 integrin as a marker of angiogenesis in
valuation of phVEGF165-stimulated angiogenesis.
hey observed focal retention of 123I-Gluco-RGD
n the SPECT 201Tl perfusion defect only in the
hVEGF165-treated pigs and not in the control
igs, although they observed no differences in 201Tl
erfusion between the treatment groups. It is not
lear why the investigators did not demonstrate
ncreased uptake of 123I-Gluco-RGD in the control
nimals, because angiogenesis is part of the natural
esponse to chronic ischemia. It is important to note
hat v3 integrin is expressed on endothelial cells
s well as inflammatory cells and smooth muscle
ells. The investigators did not define what specific
ell type 123I-Gluco-RGD is binding to within the
yocardium, and they did not correlate tracer
ptake directly with v3 expression on histologi-
al staining. The cause for the observed relationship
f 123I-Gluco-RGD retention with the endothelial
ell marker lectin is not clear, because other studies
ave suggested that similar v3 integrin-targeted
adiolabeled RGD probes bind primarily on actively
roliferating endothelial cells, not on all endothelial
ells. There were substantial circulating blood levels
f the 123I-Gluco-RGD at the time of imaging,
uggesting that focal myocardial retention in the
reated animals might simply reflect differences in
ntramyocardial blood volume or activity within the
nterstitial space associated with changes in vascular
ermeability, not necessarily active angiogenesis. rhese issues raise some concern about potential
onspecific binding or retention of 123I-Gluco-
GD.
The presence of an early VEGF-dependent hy-
erpermeable phase associated with angiogenesis
akes magnetic resonance (MR)-based vascular
ermeability imaging with contrast agents ideal for
arly identification of the angiogenic process.
erfusion-sensitive first-pass imaging of ischemic
yocardium represents an alternative to MR per-
eability imaging that also is well suited to assess-
ent of the effects of new vessel growth in the heart
22). A number of preclinical and clinical studies
ave demonstrated the value of nontargeted MR
maging for assessment of angiogenesis. These MR
pproaches have been used to evaluate angiogenic
herapy with VEGF (23,24). High-resolution con-
rast ultrasound also has been used to evaluate the
hanges in perfusion and intramuscular blood vol-
me associated with therapeutic angiogenesis (25).
Beyond physiological imaging and the targeted
maging of VEGF or v3 integrin, there are many
ther potential targets for in vivo radiotracer-based
maging of angiogenesis. Targeted imaging of
yndecan-4 and aminopeptidase-N (CD-13) repre-
ent potential alternative endothelial cell markers
or imaging of angiogenesis. Another essential
omponent of angiogenesis is signaling by mole-
ules in the ECM. The developmental endothelial
ocus-1 (Del-1) matrix protein and perlecan, a basal
amina proteoglycan, interact with other ECM
omponents during the process of angiogenesis and
epresent other potential targets for imaging of
ngiogenesis. Imaging aimed at detecting the on-
oing neovascularization could also monitor the
nflux of blood-derived macrophages and circulat-
ng endothelial precursor cells, as well as expression
f new markers specific for developing arteries in
eins (ephrins, ephrin receptors, semaphorins, and
o on).
Although radiotracer-based targeted imaging of-
ers the highest sensitivity for in vivo clinical imag-
ng, there may also be a role for targeted MR or
ltrasound imaging of angiogenesis. A number of
R agents have been evaluated for imaging of
ngiogenesis; including antibodies, peptides, and
eptidomimetics targeted at v3 integrin, vascular
ell adhesion molecule-1, intercellular adhesion
olecule-1, E-selectin, and CD-13. Because of the
ower sensitivity of MR imaging, a strategy to
mprove the signal-to-background noise ratio is
eeded. The use of targeted nanoparticles or mac-
omolecules to deliver a higher “payload” of a
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514ontrast agent to the molecular address may solve
his issue.
The dual-isotope SPECT imaging approach
utlined in the Johnson et al. (4) study offers an
dvantage over clinical indices or imaging of only
he physiological consequences of these therapies,
llowing for the simultaneous evaluation of critical
olecular signals coincident with standard physio-
ogical indices such as perfusion. This type of
argeted imaging will benefit from the availability of
ybrid SPECT-CT imaging systems which will
ermit registration of molecular and physiological8. Kastrup J, Jorgensen E, Ruck A, et al.
Direct intramyocardial plasmid vascu- 403.ure. This will facilitate correction for attenuation
nd partial volume errors and provide absolute
uantification of radiotracer retention within the
pecific regions of the heart treated. Quantitative
argeted imaging of biological markers will be
ritical for understanding the angiogenic process
nd tracking novel molecular or genetic therapies
irected at stimulating angiogenesis.
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